The estimated Net Worth of City Capital Llc Bay is at least $80.8 million dollars as of 25 June 2018. City Bay owns over 150,000 units of Kezar Life Sciences Inc stock worth over $360,893 and over the last 6 years City sold KZR stock worth over $80,488,800.
City has made over 2 trades of the Kezar Life Sciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently City bought 150,000 units of KZR stock worth $2,250,000 on 25 June 2018.
The largest trade City's ever made was selling 280,000 units of Kezar Life Sciences Inc stock on 11 June 2018 worth over $80,488,800. On average, City trades about 215,000 units every 7 days since 2018. As of 25 June 2018 City still owns at least 622,229 units of Kezar Life Sciences Inc stock.
You can see the complete history of City Bay stock trades at the bottom of the page.
City's mailing address filed with the SEC is 750 Battery St #400, San Francisco, CA 94111, USA.
Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B... et Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Kezar Life Sciences Inc executives and other stock owners filed with the SEC include: